Last reviewed · How we verify
SAL056 (56.5μg)
SAL056 is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.
SAL056 is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue. Used for Asthma (maintenance therapy), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | SAL056 (56.5μg) |
|---|---|
| Also known as | Teriparatide for Injection |
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
SAL056 acts as a topical anti-inflammatory agent when delivered directly to the respiratory tract via inhalation. By activating glucocorticoid receptors on immune cells and airway epithelium, it suppresses the production of pro-inflammatory cytokines and reduces mucus production, airway edema, and eosinophilic infiltration. This mechanism makes it suitable for chronic inflammatory airway diseases.
Approved indications
- Asthma (maintenance therapy)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Tremor
- Headache
- Dysphonia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAL056 (56.5μg) CI brief — competitive landscape report
- SAL056 (56.5μg) updates RSS · CI watch RSS
- Shenzhen Salubris Pharmaceuticals Co., Ltd. portfolio CI